Menu
Search
|

Menu

Close
X

Voyager Therapeutics Inc VYGR.OQ (NASDAQ Stock Exchange Global Select Market)

18.70 USD
+0.36 (+1.96%)
As of Jul 21
chart
Previous Close 18.34
Open 18.31
Volume 167,244
3m Avg Volume 169,686
Today’s High 19.81
Today’s Low 18.31
52 Week High 31.91
52 Week Low 8.10
Shares Outstanding (mil) 26.90
Market Capitalization (mil) 557.18
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.80 Mean rating from 10 analysts

KEY STATS

Revenue (mm, USD)
FY18
1
FY17
10
FY16
14
FY15
17
EPS (USD)
FY18
-0.627
FY17
-2.669
FY16
-1.586
FY15
-1.489
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
67.04
5.73
Price to Book (MRQ)
vs sector
5.11
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.00
16.84
LT Debt to Equity (MRQ)
vs sector
0.00
12.51
Return on Investment (TTM)
vs sector
-35.17
14.61
Return on Equity (TTM)
vs sector
-45.36
16.34

EXECUTIVE LEADERSHIP

Mark Levin
Independent Chairman of the Board, Since 2014
Salary: --
Bonus: --
G. Andre Turenne
President, Chief Executive Officer, Since 2018
Salary: --
Bonus: --
Allison Dorval
Principal Financial Officer and Principal Accounting Officer, Since 2018
Salary: --
Bonus: --
Matthew Ottmer
Chief Operating Officer, Since 2017
Salary: --
Bonus: --
Robert Pietrusko
Senior Vice President - Regulatory Affairs, Since 2014
Salary: $174,792.00
Bonus: $1,161.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

75 Sidney St
CAMBRIDGE   MA   02139-4134

Phone: +1857.2595340

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company's pipeline consists of programs for CNS indications, including advanced Parkinson's disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington's disease; Friedreich's ataxia; frontotemporal dementia/Alzheimer's disease, and severe chronic pain. The Company's clinical candidate, VY-AADC01, is an adeno-associated virus (AAV) gene therapy product candidate, for the treatment of advanced Parkinson's disease. VY-AADC01 consists of the AAV2 capsid, which has been used in multiple AAV gene therapy clinical trials for various diseases, and the cytomegalovirus promoter that drives expression of the aromatic L-amino acid decarboxylase (AADC) transgene. Its pipeline also includes VY-SOD101, VY-FXN01, VY-HTT01, VY-TAU01 and VY-NAV01.

SPONSORED STORIES